Author’s Reply to Pestana et al. Comment on: “Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?”

Funding

No sources of funding were used to conduct this study or prepare this manuscript.

Conflicts of Interests

Afsaneh Alavi is a consultant for AbbVie, BI, Janssen, InflaRx, Novartis, and UCB and an investigator for BI, Processa. Laura Raffals has no conflicts of interest that are directly relevant to the content of this letter.

Ethics Approval

Not applicable.

Consent to Participate

Not applicable.

Consent to Publish

Not applicable.

Availability of Data and Material

Not applicable.

Code Availability

Not applicable.

留言 (0)

沒有登入
gif